Pulmatrix Inc (PULM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.39+2.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PULM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -44.3% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 5.3% |
Growth built into the price is above our model estimate.
The price assumes 49.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers
PULM — private placement
Dated 2026-04-21
Other Events On April 16, 2026, the Company closed its previously announced private placement of its Series B Preferred Stock, par value $0.0001 per share (the “ Private Placement ”). The Private Placement was exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions…
Why it matters: Good use of funds can make the company stronger and help it grow.
Supportive ifManagement shares clear plans for how to use funds from the recent placement.
Worry ifManagement does not explain how they will use the funds.
Why it matters: The merger is key for Pulmatrix's growth. Closing it will combine resources and pipelines.
Supportive ifThe merger will close in Q3 2026 as planned. It meets all usual conditions.
Worry ifThe merger fails to close by the end of Q3 2026.
Why it matters: These results will show if Pulmatrix is handling its cash and costs well.
Watch forResults show a big drop in net loss compared to earlier quarters.
Also watch forResults show an increase in net loss compared to previous quarters.
Why it matters: Finishing this deal could help Pulmatrix grow. It can also make their market position stronger.
Supportive ifAn official announcement that the Eos SENOLYTIX deal is done.
Worry ifNews about delays or failure to finish the deal.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$195 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $647 loss on $10,000 · 6.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,707 loss on $10,000 · 77.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Licensing deals could bring in needed money. They also support Pulmatrix's technology.
Supportive ifPulmatrix announces a licensing deal or plans to make money from PUR1900 or PUR3100.
Worry ifThere are no licensing deals. No money-making efforts are reported.
Why it matters: Updates on cash runway will show if Pulmatrix can operate until the merger ends.
Worry ifManagement says they have enough cash to run the business until Q3 2026.
Less concerning ifManagement says cash will run out before the merger ends.
Why it matters: Converting Series B Preferred Stock could change the share structure. It may also help raise money for operations.
Watch forHolders of Series B Preferred Stock begin converting their shares into common stock at the $2.20 price.
Also watch forNo conversions happen. This shows a lack of investor confidence or interest.
Why it matters: If the health care sector's revenue growth speeds up, it could help Pulmatrix's outlook.
Supportive ifHealth care sector revenue growth accelerates back toward 10% or higher.
Worry ifRevenue growth is slowing down. It is now below current levels.
Why it matters: Good funding can help the company grow and keep running.
Watch forA new private placement announcement that brings in a lot of money.
Also watch forFailure to secure new capital through private placements.
Why it matters: Success in the Phase 3 trial could lead to royalties and validate Pulmatrix's technology.
Supportive ifCipla announces the start of the Phase 3 trial for PUR1900.
Worry ifCipla delays or cancels the Phase 3 trial for PUR1900.
Why it matters: Progress on PUR3100 is very important for Pulmatrix's pipeline. It can help make money.
Supportive ifFDA acceptance of the IND for PUR3100 and initiation of the Phase 2 study.
Worry ifDelays in starting the Phase 2 study or negative updates on the IND.
Why it matters: Cash levels affect how Pulmatrix can operate. They also impact funding for the merger.
Worry ifCash and cash equivalents remain above $2 million.
Less concerning ifCash and cash equivalents fall below $2 million.
Why it matters: Licensing PUR1900 can provide new revenue streams for Pulmatrix.
Supportive ifAn announcement of a licensing agreement for PUR1900 with a partner.
Worry ifNo progress on licensing or monetizing PUR1900 in the next quarter.